This study aimed to design, synthesize, and characterize novel ruthenium (II) Schiff base complexes as potential antimicrobial agents to address the growing crisis of multidrug-resistant bacterial infections. Despite advances in antibiotic development, resistance to existing drugs, particularly in Staphylococcus aureus and Escherichia coli-demands new compounds with alternative mechanisms of action. A key research gap lies in the limited exploration of pyridine-imine Schiff base ruthenium complexes with systematic substitution (-Br, -OH) and a comparison between simple Ru (II) and Ru(II)-p-cymene architectures. Ligands and their Ru (II) complexes were synthesized and characterized by FT-IR, UV-Vis, ¹H NMR, and melting point. Antimicrobial activity was evaluated using agar disc diffusion against both bacterial strains at concentrations ranging from 125 to 1000 µg/mL, with data analyzed using two-way ANOVA and Fisher’s LSD test (α = 0.05). Results showed Ru (II) complexes exhibited significantly higher inhibition than free ligands (p ≤ 0.05), with bromo- and hydroxy-substituted cymene complexes (e.g., L-C2, L1-C2) displaying the strongest activity (up to 14 -15 mm zones). Although all compounds were less potent than gentamycin, the enhanced bioactivity upon metal coordination supports Tweedy’s chelation theory. These findings validate Ru (II)-Schiff base complexes as promising scaffolds for future antimicrobial development, warranting further studies on MIC, toxicity, and antifungal activity.
No takes yet. Share an insight, caveat, or question.
Nyang’ate et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: